Yposkesi, a leading Contract Development and Manufacturing Organization (CDMO) for preferred access and reserved capacity for cGMP grade viral vector production, today announces it produced the viral vectors used in the gene therapy-based clinical trial in patients with Fanconi anemia. In this study, the authors demonstrate for the first time the production of blood cells derived from the patients genetically corrected stem cells. The work on Fanconi anemia patients is published in Nature (...)
The agenda of this shareholder’s meeting is to amend the Articles of Association in order to create the position of observer on the Board of Directors, and to appoint BOLD - Business Opportunities for L’Oréal Development to this position in accordance with the announcement made at the last fund-raising event.
In line with its commitment to sustainable development, Braskem, the world’s largest biopolymer producer, announces the renewal of its partnership with Altar, a France-based startup specializing in the development of microorganism lineages in automated cultivation systems. Forged two years ago, the partnership strengthens the company’s strategy for the research and development of renewable (...)
Clinical evaluation begins for Diagen™ to take patients’ genomic profiles into account along the nephrology care pathway TRAASER, an innovative startup specializing in medical genomics, announces the start of clinical evaluation for its Diagen™ solution as part of the SAGE project, laureate of Bpifrance’s Digital Innovation Competition organized for France’s “Investments for the Future” program, to develop medical genomics for kidney diseases. In collaboration with the Paris AP-HP public (...)
Servier appoints Yposkesi for lentiviral vector GMP-manufacturing in CAR-T cell development technology Service agreement gives Servier access to Yposkesi’s robust production capacity Servier, an international independent pharmaceutical company, and Yposkesi, a leading CDMO for gene therapy viral vector manufacturing, today announce that they have signed a manufacturing service agreement. Servier selected Yposkesi to develop and GMP manufacture lentiviral vectors to support allogenic CAR-T (...)
A committee of independent experts met on 19–20 March to choose five biotech projects and six young start-ups for the fourth editions of Genopole’s Shaker and Booster accompaniment programs. The innovations proposed by the eleven laureates will bring scientific and technological advances to the fields of healthcare, cosmetics, the environment, industrial biotechnologies, and beyond. Read (...)
Global Bioenergies (Euronext Growth : ALGBE) released its 2018 financial statements, audited, certified and approved by the Board of Directors Meeting. These yearly figures report a net loss of €13.6m for the 2018 financial year, a slight improvement over 2017, and a cash position of €10.3 million as at 31 December 2018.
New phase for the H2020 Optisochem project after 18 months of activity Sugars from wheat straw produced at Clariant’s Sunliquid® pre-commercial plant have been shipped to Global Bioenergies’ Leuna demo plant Successful test runs for production of straw-based isobutene, batches de livered to INEOS for evaluation Read more
Genopole, the biocluster located in the Greater Paris region is the first European park to receive the Association of University Research Parks (AURP) award. This is the first time a member outside the US has been acknowledged. The announcement was made during AURP’s International Annual Conference in Baltimore (Maryland).
ENTEROME SA, a clinical-stage biotech company developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer, has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company Limited (“Takeda”). The agreement covers Enterome’s lead investigational drug candidate EB8018 in patients with Crohn’s disease, with the potential to expand to other gastrointestinal (GI) disorders and liver (...)